 <h1>Besponsa Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>inotuzumab ozogamicin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about inotuzumab ozogamicin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Besponsa.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to inotuzumab ozogamicin: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received inotuzumab ozogamicin.A higher post-HSCT non-relapse mortality rate occurred in patients receiving inotuzumab ozogamicin.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, inotuzumab ozogamicin (the active ingredient contained in Besponsa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking inotuzumab ozogamicin:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough or hoarseness</li>
<li>coughing up blood</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>lower back or side pain</li>
<li>nosebleeds</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>paralysis</li>
<li>pinpoint red spots on the skin</li>
<li>prolonged bleeding from cuts</li>
<li>red or dark brown urine</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of inotuzumab ozogamicin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>nausea</li>
<li>stomach pain</li>
<li>swelling or inflammation of the mouth</li>
<li>vomiting</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to inotuzumab ozogamicin: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (51%) (42% of which were Grade 3 or higher), neutropenia (49%) (48% of which were Grade 3 or higher), anemia (36%) (24% of which were Grade 3 or higher), leukopenia (35%) (33% of which were Grade 3 or higher), febrile neutropenia (26%) (all of which were Grade 3 or higher), lymphopenia (18%) (16% of which were Grade 3 of higher)</p>
<p><b>Common</b> (1% to 10%): Pancytopenia (e.g., bone marrow failure, febrile bone marrow aplasia, pancytopenia)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (48%) (28% of which were Grade 3 or higher)</p>
<p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion related reaction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Muscle hemorrhage<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Conjunctival hemorrhage, eyelid bleeding<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (12%)</p>
<p><b>Common</b> (1% to 10%): Lipase increased, amylase increased, hyperuricemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Vaginal hemorrhage (10%)</p>
<p><b>Frequency not reported</b>: Menorrhagia, hematuria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Hyperbilirubinemia (21%), transaminases increased (26%), gamma-glutamyltransferase increased (21%), alkaline phosphatase increased (13%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Epistaxis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (35%), pyrexia (32%), chills (11%)</p>
<p><b>Frequency not reported</b>: Hemotympanum<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hemorrhage (33%) (5% of which were Grade 3 or higher)</p>
<p><b>Common</b> (1% to 10%): QT prolonged</p>
<p><b>Frequency not reported</b>: Intracranial hemorrhage, subdural hematoma<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Ecchymosis, hemorrhage subcutaneous, mesenteric hemorrhage, petechiae, post-procedural hematoma<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (31%), abdominal pain (23%), diarrhea (17%), constipation (17%), vomiting (15%), stomatitis (13%)</p>
<p><b>Common</b> (1% to 10%): Abdominal distention, ascites</p>
<p><b>Frequency not reported</b>: GI hemorrhage, hemorrhagic gastritis, gingival bleeding, hematemesis, hematochezia, hemorrhoidal hemorrhage, intraabdominal hemorrhage, lip hemorrhage, upper/lower GI hemorrhage, mouth hemorrhage, oral mucosa hematoma, rectal hemorrhage<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Besponsa (inotuzumab ozogamicin)." Wyeth Laboratories, Philadelphia, PA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How does Besponsa work to treat acute lymphoblastic leukemia (ALL)?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Besponsa (inotuzumab ozogamicin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Besponsa &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to inotuzumab ozogamicin: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Thrombocytopenia (51%) (42% of which were Grade 3 or higher), neutropenia (49%) (48% of which were Grade 3 or higher), anemia (36%) (24% of which were Grade 3 or higher), leukopenia (35%) (33% of which were Grade 3 or higher), febrile neutropenia (26%) (all of which were Grade 3 or higher), lymphopenia (18%) (16% of which were Grade 3 of higher)</p><p><b>Common</b> (1% to 10%): Pancytopenia (e.g., bone marrow failure, febrile bone marrow aplasia, pancytopenia)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (48%) (28% of which were Grade 3 or higher)</p><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion related reaction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Muscle hemorrhage<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Conjunctival hemorrhage, eyelid bleeding<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (12%)</p><p><b>Common</b> (1% to 10%): Lipase increased, amylase increased, hyperuricemia</p><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Vaginal hemorrhage (10%)</p><p><b>Frequency not reported</b>: Menorrhagia, hematuria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Hyperbilirubinemia (21%), transaminases increased (26%), gamma-glutamyltransferase increased (21%), alkaline phosphatase increased (13%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Epistaxis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (35%), pyrexia (32%), chills (11%)</p><p><b>Frequency not reported</b>: Hemotympanum<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hemorrhage (33%) (5% of which were Grade 3 or higher)</p><p><b>Common</b> (1% to 10%): QT prolonged</p><p><b>Frequency not reported</b>: Intracranial hemorrhage, subdural hematoma<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Ecchymosis, hemorrhage subcutaneous, mesenteric hemorrhage, petechiae, post-procedural hematoma<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (31%), abdominal pain (23%), diarrhea (17%), constipation (17%), vomiting (15%), stomatitis (13%)</p><p><b>Common</b> (1% to 10%): Abdominal distention, ascites</p><p><b>Frequency not reported</b>: GI hemorrhage, hemorrhagic gastritis, gingival bleeding, hematemesis, hematochezia, hemorrhoidal hemorrhage, intraabdominal hemorrhage, lip hemorrhage, upper/lower GI hemorrhage, mouth hemorrhage, oral mucosa hematoma, rectal hemorrhage<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Besponsa (inotuzumab ozogamicin)." Wyeth Laboratories, Philadelphia, PA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How does Besponsa work to treat acute lymphoblastic leukemia (ALL)?</li>
</ul><h2>More about Besponsa (inotuzumab ozogamicin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Besponsa &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>